Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.
Wakelee HA, Dahlberg SE, Brahmer JR, Schiller JH, Perry MC, Langer CJ, Sandler AB, Belani CP, Johnson DH; Eastern Cooperative Oncology Group. Wakelee HA, et al. Among authors: perry mc. Lung Cancer. 2012 Jun;76(3):410-5. doi: 10.1016/j.lungcan.2011.12.006. Epub 2012 Jan 21. Lung Cancer. 2012. PMID: 22266041 Free PMC article.
Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599.
Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A, Johnson DH. Brahmer JR, et al. Among authors: perry mc. J Thorac Oncol. 2011 Jan;6(1):103-8. doi: 10.1097/JTO.0b013e3181fa8efd. J Thorac Oncol. 2011. PMID: 21079521 Free PMC article. Clinical Trial.
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.
Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH; Eastern Cooperative Oncology Group. Wakelee HA, et al. Among authors: perry mc. Lung Cancer. 2005 Jun;48(3):389-97. doi: 10.1016/j.lungcan.2004.11.007. Epub 2005 Jan 5. Lung Cancer. 2005. PMID: 15893008 Clinical Trial.
Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ. Belani CP, et al. Among authors: perry mc. J Clin Oncol. 2008 Jan 20;26(3):468-73. doi: 10.1200/JCO.2007.13.1912. J Clin Oncol. 2008. PMID: 18202422 Clinical Trial.
A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy.
Crawford J, Robert F, Perry MC, Belani C, Williams D; Anemia Prevention in NSCLC Group. Crawford J, et al. Among authors: perry mc. J Thorac Oncol. 2007 Mar;2(3):210-20. doi: 10.1097/JTO.0b013e318031cd9a. J Thorac Oncol. 2007. PMID: 17410044 Free article. Clinical Trial.
253 results